LinkedIn image ad examples

Discover clinical development strategies for advancing CAR-T into autoimmune and chronic disease indications. Download the whitepaper.

Download the whitepaper and explore how patient needs, risk tolerance and long-term follow-up reshape immunotherapy trials beyond oncology.

Imaging is more than image collection. It’s the workflow connecting sites, image quality, readers, central review and clinical endpoints. Collective Minds brings that journey together in one centralized platform, giving sponsors greater visibility across the imaging workflow. Connect your imaging workflow. Keep your trials moving toward endpoints.

Clinical trial imaging doesn’t happen in isolation. It connects sites, quality control, readers, central review and ultimately the clinical endpoints that matter. Collective Minds brings these workflows together in one centralized platform, helping sponsors gain visibility and reduce fragmentation across their studies. One connected imaging workflow. A clearer path to your endpoints.

You don’t have to choose between process efficiency and a cleaner label. Nutracore® LFP is an organic lubricant that delivers superior flow for capsule and tablet formulations, helping you reduce processing issues and keep production moving. Discover how easily Nutracore LFP integrates into your process to support reliable, high‑quality output.

Elevate your pathology lab with Aiforia® Breast Cancer Suite – enhancing precision, speed, and diagnostic accuracy with cutting-edge AI technology. Aiforia® Breast Cancer Suite consists of AI models with an optimized interactive user interface that supports pathologists in the histological grading of breast cancer and in the assessment of breast cancer IHC markers. Request a demo to see a more detailed overview of the features. ⬇️

Breast Cancer Awareness Month is a powerful reminder of the vital role pathology plays in patient outcomes. But growing workloads demand faster, more consistent diagnostic insights. Aiforia’s Breast Cancer Suite–a comprehensive portfolio of CE-IVD marked AI models–empowers pathologists to deliver faster, more consistent, data-driven insights, improving diagnostic accuracy and patient outcomes. Learn more: https://lnkd.in/dApWDa3k/?utm_campaign=BCSuite%25E2%2580%2593Leadform%25E2%2580%2593Q42026&utm_source=linkedin&utm_medium=paid&utm_id=1229053903&hsa_acc=502575710&hsa_cam=1229053903&hsa_grp=896190383&hsa_ad=1592710023&hsa_net=linkedin&hsa_ver=3

Your revenue cycle data tells you what happened. But what if you could see what’s happening across 500M+ annual transactions? Introducing Aptarro Prism, the reimbursement intelligence platform that transforms decades of reimbursement data across thousands of providers into actionable insights. Spot emerging denial trends, understand payer behavior, and make smarter decisions backed by intelligence that gets sharper with every outcome.

Is calprotectin part of your product offering? Calpro is looking for distribution companies to add CalproLab® ELISA, Calpro EasyExtract® and CalproSmart® to their portfolio. Meet us at MEDICA in Düsseldorf, 16–19 November, and discuss your market. Book a meeting: https://lnkd.in/eyPDdxFe

Chinese National Medical Products Administration has approved our next-generation anti-wrinkle treatment, designed with PEARL™ Technology, for the improvement of frown lines in adults. This approval underscores Galderma’s continued leadership and further expands the global reach of our innovative anti-wrinkle solution. Learn more: https://lnkd.in/e8uKVgRp #AdvancingDermatology #SkinSciencebyGalderma #ForInvestors

#1 most-cited antibodies in the world. Here's why that matters for your data. When running multiplex or multiomic experiments, reliable antibody performance is critical. CST® products have been cited 5x more often per product than any other supplier’s, and >99% of our recombinant antibodies are application-validated and made in house. Download the infographic to learn more.

Payer rules change. Denial patterns shift. And your team is expected to keep up with it all. What if you could see those changes before the denial? Pinpoint emerging trends across a network, predict and prevent denials, and turn revenue cycle data into intelligence at the point-of-decision.

💚 Feeling fine doesn't always tell the full story. Many health conditions develop quietly, often with little or no obvious symptoms. That's why regular health checks can be so important. Our Well Person Check provides a comprehensive overview of your health, including heart health, blood pressure, cholesterol, diabetes markers, liver and kidney function, vitamin levels, thyroid function, inflammation screening and selected cancer markers. Think of it as a health MOT, giving you the information you need to make informed decisions about your wellbeing. Because when it comes to your health, knowledge really is power 💪 ✨ Learn more: https://lnkd.in/eNyCKc5W #emeraldurgentcare #urgentare #healthassessments #healthchecks #northernireland

In a successful team, it's important to stay open to new ideas and not be afraid of change. At Gedeon Richter, listening to each other's ideas, sharing experiences, and new and better ways of approaching our work. are all part of our everyday work. Change inspires us to seek new opportunities. We build on the experience of the past while exploring new directions. Our goal is to continue doing work that creates real value for patients in the future. Discover the career opportunities waiting for you at Gedeon Richter!

At Gedeon Richter, we often face complex decisions that require us to consider multiple perspectives. In these situations, it's important to understand the circumstances, have the confidence to make decisions, and recognise how our work can impact patients' lives. What makes our work particularly exciting is the opportunity to turn complex challenges into meaningful solutions that can make a real difference in pharmaceutical manufacturing. For 125 years, we have been working to contribute to people's health and quality of life through our knowledge and expertise. Discover the career opportunities waiting for you at Gedeon Richter!

What does it take to move #NewApproachMethodologies (#NAMs) from promising research alternatives to reliable research tools? Successful implementation goes beyond just adopting new technologies. It requires careful consideration of biological relevance, reproducibility, and fit-for-purpose validation to generate meaningful and reliable data. In our latest blog, we explore these important considerations and BioIVT’s strong position in supporting researchers’ biospecimen requirements at any stage of development, from target to clinic. Read the full piece: https://hubs.ly/Q04BxQnS0

While cellular material can be manually isolated in-house, the process requires expertise, bandwidth &/or capacity that many researchers do not have available. We can fill that gap so you can focus on your research. Our extensive #biospecimens portfolio includes readily-available, high-quality, fresh and cryopreserved cellular material from a diverse range of highly characterized donors, including purified subsets like T, NK, CD3, CD4, etc. Take a look at the options: https://lnkd.in/eWfQT5Qr

From autumn fields to high-quality botanicals. 🌾🍂 As October brings cooler days and shifts the natural pace of the Mediterranean landscape, our agricultural focus pivots to seasonal soil preparation and crop management. October is a crucial transitional month at Boniser: it’s when we protect soil physiology, check moisture, and set the groundwork for the next generation of officinal plants. For us, where we come from isn't just a geographic origin—it’s an ongoing commitment to working alongside the seasons. Discover how our territory drives our quality 👉 https://lnkd.in/d64TCZ5S #Boniser #NatureOurOnlyInspiration #WhereWeComeFrom #MediterraneanAutumn

Most AI tools can't answer the questions regulators will ask. ◾Can this output be traced back to its source? ◾Can the methodology be reproduced under audit? ◾Was every screening decision logged with a timestamp? For most general-purpose GenAI tools, the answer is no. The problem isn't AI. It's the wrong AI. Life sciences teams are under pressure to move faster, faster literature reviews, faster HEOR dossiers, faster regulatory submissions. So when an AI tool promises to summarize 500 abstracts in minutes, the appeal is obvious. But speed without traceability isn't a shortcut. It's a liability. ◾A missed citation in a safety review puts patients at risk. ◾A hallucinated effect size distorts a cost-effectiveness model. ◾Undocumented screening decisions delay approvals. Regulatory-Grade AI is different by design. It's built around four principles the industry is converging on: ◾Defensibility over convenience, every data point traces back to source ◾Human expertise in the loop, AI accelerates decision making, it doesn't replace it ◾Audit-ready by default, every search, citation, and decision is logged ◾Your evidence stays yours, no inadvertent sharing your confidential data with third-party LLMs The deeper opportunity isn't speed. It's strategic. When literature reviews are conducted on a regulatory-grade platform, they stop being one-off documents and become reusable organizational assets, validated once, available across regulatory submissions, HEOR dossiers, and medical affairs communications. Evidence silos dissolve. Teams stop reworking the same evidence.And patients get access to treatments faster. The question isn't whether AI belongs in regulated workflows. It's whether the AI you're using was actually built for them. Learn more about DistillerSR

Join us on November 17, 2026, for the fifth and final webinar in our free series: The value of Automation – Practical application insights for smarter labs In this session we'll explore: Maximizing digital PCR efficiency – Automated QIAcuity® nanoplate setup with epMotion Digital PCR supports precise, absolute nucleic acid quantification across a wide range of applications. By removing the need for standard curves, it can help laboratories generate robust and reproducible results. Join us for a practical webinar with Dr. Gerald Schock, Director of Product Management for Digital PCR Instruments at Qiagen. Together, we’ll explore how automating QIAcuity® Nanoplate setup on the epMotion® 5073 can simplify dPCR sample preparation, reduce hands-on time, and help limit operator-dependent variability compared with manual pipetting. We’ll also look at how the compact, open epMotion® 5073 platform supports the automated preparation of different QIAcuity® Nanoplate formats, including 26k 24-well and 8.5k 96-well Nanoplates. Why attend? • Understand how digital PCR supports precise and reproducible nucleic acid quantification. • Learn how automated nanoplate setup can simplify dPCR sample preparation. • Explore ways to reduce hands-on time and operator-dependent variability. • Discover how the epMotion® 5073 supports different QIAcuity® Nanoplate formats. • See how automation can provide more walk-away time during routine workflows. Leave with a clearer view of how automated QIAcuity® Nanoplate setup can support efficient and reproducible digital PCR workflows. Join us and explore practical ways to increase efficiency in your laboratory. 📅 November 17, 2026 | 4:00 p.m. CET Join us live and bring your questions about laboratory automation.

Your healthcare systems generate valuable data every day. But can every team access the insights they need? Kodjin Data Platform connects clinical, operational, and financial data from multiple sources into a unified, governed data foundation. With AI-assisted conversational analytics, clinicians, operations managers, and executives can explore data using natural-language questions and access insights relevant to their roles, without writing SQL or waiting for custom reports. Make healthcare data accessible and actionable across your organization. Discover Kodjin Data Platform

𝗢𝗻𝘁𝗱𝗲𝗸 𝗵𝗲𝘁 𝗲-𝗵𝗲𝗮𝗹𝘁𝗵 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝘃𝗮𝗻 𝗘𝗺𝗯𝗹𝗼𝗼𝗺 Embloom ondersteunt elke stap in het behandelproces, zodat zorg effectiever én cliëntgerichter wordt: 🟠 Voor behandelaren: Meer tijd voor écht contact en toegang tot een flexibel inzetbaar e-health platform 🟠 Voor cliënten: Zelf aan de slag en meer regie over hun eigen herstelproces 🟠 Voor organisaties: Meer tijd voor zorg en een hogere cliënttevredenheid 👉 Ervaar zelf de mogelijkheden en probeer Embloom 2 weken gratis uit: https://lnkd.in/ePtJJg-c

We're skipping the booth at #BIO2026. Instead, we're bringing Aika 2.0 directly to you. From June 22-June 25, eligible attendees can book private rides across San Diego and experience Aika 2.0 live. Aika is the first end-to-end solution for clinical development, connecting every stage from protocol design to regulatory strategy. Beyond automation, it enables teams simulate trial design and budgets. Clinical trials just got a faster ride 🏎️ 🔥 Book your ride and connect with us 🤝 https://lnkd.in/eX2w34Bx #AikaLaunch #ProductLaunch #BIO2026 #SanDiego #Convention #Biotech #Pharma #ClinicalTrials #ClinicalDevelopment #AI

Most viewers are fast at the first site. Add the fifth, the tenth, the twentieth, and load times start to slip. StreamVue holds the same speed across the entire enterprise, streaming from the PACS you already have.